Scilex Holding Co (SCLX) · Nov 20, 2026 · Delisting

Scilex delisting notice exposes Nasdaq risk as cash pressure mounts

Nasdaq deficiency notice — MVLS below $35M for 30 consecutive business days; compliance deadline May 17, 2027

Scilex’s delisting filing gives the company until May 17, 2027 to restore Nasdaq compliance, adding pressure to an already cash-strained pain-drug business.

Scilex is a small commercial-stage pain-drug company trying to grow ZTlido while building early commercialization for GLOPERBA and ELYXYB; its latest reported balance sheet showed only about $0.6 million of cash and substantial dependence on future product sales and outside financing.

The filing adds a material listing problem, not a routine warning. Nasdaq says Scilex’s market value of listed securities stayed below the $35 million requirement for 30 straight business days, and the company also fails the alternative standards based on stockholders’ equity and net income.

The immediate trading impact is limited, but the operational clock has started. SCLX and SCLXW remain listed for now, while Nasdaq gives Scilex until May 17, 2027 to maintain at least $35 million of market value for 10 consecutive business days. 〔0〕 〔1〕

The deeper issue is that the filing confirms weak financial-market support around a business already short on liquidity. Scilex says it is only evaluating options to regain compliance and offers no committed transaction, operating improvement, or financing plan that would solve the deficiency. The company’s recent late filing for the September 30, 2026 quarter adds execution uncertainty, although the 8-K itself does not explain the cause.

Bottom line: This is a clear setback to Scilex’s current story: the company now must repair both its listing status and the financial conditions that caused the deficiency. The six-month window avoids an immediate delisting, but it does not remove the underlying pressure.

What to watch next

Regain Nasdaq compliance by May 17, 2027

Original filing on SEC EDGAR

Scilex delisting notice exposes Nasdaq risk as cash pressure mounts | SCLX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.